<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01260025</url>
  </required_header>
  <id_info>
    <org_study_id>2009L01132</org_study_id>
    <nct_id>NCT01260025</nct_id>
  </id_info>
  <brief_title>Tolerability and Pharmacokinetics of M2ES in the Treatment of Advanced Solid Tumor</brief_title>
  <official_title>Dose Escalation Study of Tolerability and Pharmacokinetics of PEDylated Recombinant Human Endostatin(M2ES)in the Treatment of Advanced Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. MTD and DLT of M2ES

        2. Pharmacokinetics of M2ES
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients received infusion of M2ES for 120 minutes weekly（d1,d8,d15）by calculated pump and
      underwent evaluation of vital signs including blood pressure, pulse, respiratory rate, and
      temperature before treatment, at intervals during infusion, and hourly for 6 hours after
      infusion. After infusion, patients underwent serial pharmacokinetic sampling. All patients
      were seen weekly during the study therapy and follow-up and underwent evaluation with
      physical examination including ECOG performance status, vital signs, and laboratory
      evaluation with complete blood count with manual differential, chemistry evaluation,
      prothrombin time/partial thromboplastin time, and urinalysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maxinum tolerated dose of M2ES</measure>
    <time_frame>one month</time_frame>
    <description>To assess the adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response rate</measure>
    <time_frame>one month</time_frame>
    <description>To assess the tumor response rate of M2ES in patients with solid, malignant tumours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic effect</measure>
    <time_frame>one month</time_frame>
    <description>Pharmacokinetic effect of M2ES in patients with solid, malignant tumours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DLT of M2ES</measure>
    <time_frame>one month</time_frame>
    <description>To assess the adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Tolerability</condition>
  <condition>Pharmacokinetics</condition>
  <condition>Endostatin</condition>
  <arm_group>
    <arm_group_label>PEDylated Recombinant Human Endostatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEDylated Recombinant Human Endostatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEDylated Recombinant Human Endostatin</intervention_name>
    <description>The initial dose of PEDylated Recombinant Human Endostatin (M2ES) will be 7.5mg/m2.Dose Escalation to a next higher level will occur when 3 patients in the same dose level complete 28 days of continuous treatment without experiencing a dose-limiting toxicity.</description>
    <arm_group_label>PEDylated Recombinant Human Endostatin</arm_group_label>
    <other_name>M2ES</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 65 years;Genders eligible for study: both;

          -  Histologic diagnosis of solid malignancies ;

          -  Performance status of 0 or 1;

          -  Tumor not amenable to standard curative or palliative therapy;

          -  life expectancy beyond 3 months;

          -  Ability to give signed informed consent

        Exclusion Criteria:

          -  Pregnancy or lactation;

          -  Had a history of brain metastasis or a primary brain tumor;

          -  An active, potentially severe autoimmune disease;

          -  Serum creatinine ≥1.5mg/dl or a calculated creatinine clearance ＜60ml/min; WBC count &lt;
             2.0×109/L，hemoglobin &lt; 90g/L，and platelet count &lt; 100×109/L; Total bilirubin value &lt;
             2.0 times the upper limit of normal (ULN), ALT level &lt; 2.0 times ULN, AST &lt; 2.0 times
             ULN;

          -  Positive of anti-HIV antibodies;

          -  An active infection;

          -  had received chemotherapy or immunotherapy within the prior 4 weeks before study entry

          -  Participation in a clinical study during the last 28 days

          -  QTc with Bazett's correction unmeasurable or ≥ 480 msec on screening ECG
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Zhang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2010</study_first_submitted>
  <study_first_submitted_qc>December 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2010</study_first_posted>
  <last_update_submitted>February 14, 2012</last_update_submitted>
  <last_update_submitted_qc>February 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Li Zhang</investigator_full_name>
    <investigator_title>Profressor</investigator_title>
  </responsible_party>
  <keyword>Tolerability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Endostatin</keyword>
  <keyword>antiangiogenesis</keyword>
  <keyword>cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endostatins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

